Neurocrine Biosciences Q1 2025 Update
Ticker: NBIX · Form: 10-Q · Filed: 2025-05-05T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report, biotech
Related Tickers: NBIX
TL;DR
NBIX Q1 2025 financials filed. Key balance sheet and revenue data available.
AI Summary
Neurocrine Biosciences Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial filings indicate a fiscal year end of December 31. Key financial data points such as common stock, additional paid-in capital, and retained earnings as of December 31, 2024, and for the period ending March 31, 2025, are detailed. The filing also includes information on product revenue and collaboration revenue for the first quarters of 2025 and 2024.
Why It Matters
This filing provides investors with a quarterly update on Neurocrine Biosciences' financial performance and key balance sheet items, crucial for assessing the company's health and investment potential.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing (10-Q) with no immediate red flags or significant new disclosures that would suggest a high risk.
Key Numbers
- 2025-03-31 — Period End Date (Quarterly reporting period)
- 2024-12-31 — Previous Year End Date (Comparison point for balance sheet items)
- 2025-01-01 to 2025-03-31 — Q1 2025 Reporting Period (Revenue and balance sheet changes)
- 2024-01-01 to 2024-03-31 — Q1 2024 Reporting Period (Comparison for revenue trends)
Key Players & Entities
- NEUROCRINE BIOSCIENCES INC (company) — Filer
- 20250331 (date) — Period of Report
- 20250505 (date) — Filed as of Date
- 330525145 (company) — EIN
- DE (company) — State of Incorporation
- 1231 (date) — Fiscal Year End
- 000-22705 (company) — SEC File Number
FAQ
What were Neurocrine Biosciences' product revenues for the first quarter of 2025?
The filing indicates product revenue for the period from January 1, 2025, to March 31, 2025, but the specific dollar amount is not provided in the extracted text.
How did collaboration revenue in Q1 2025 compare to Q1 2024?
The filing references collaboration revenue for both periods (January 1, 2025, to March 31, 2025, and January 1, 2024, to March 31, 2024), but the specific figures are not detailed in the provided text.
What is the company's fiscal year end?
The company's fiscal year ends on December 31, as stated in the filing.
What are the key balance sheet components reported as of December 31, 2024?
The filing lists common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings as of December 31, 2024.
When was this 10-Q filing submitted?
This 10-Q filing was submitted on May 5, 2025.
From the Filing
0000914475-25-000100.txt : 20250505 0000914475-25-000100.hdr.sgml : 20250505 20250505160352 ACCESSION NUMBER: 0000914475-25-000100 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 95 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250505 DATE AS OF CHANGE: 20250505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 25912812 BUSINESS ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 10-Q 1 nbix-20250331.htm 10-Q nbix-20250331 FALSE 2025 Q1 0000914475 12/31 http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent one one 345 xbrli:shares iso4217:USD iso4217:USD xbrli:shares nbix:non-clinicalStageCompound nbix:preclinicalCandidate nbix:undisclosedProgram nbix:geneTherapyProgram xbrli:pure nbix:day nbix:segment 0000914475 2025-01-01 2025-03-31 0000914475 2025-04-30 0000914475 2025-03-31 0000914475 2024-12-31 0000914475 us-gaap:ProductMember 2025-01-01 2025-03-31 0000914475 us-gaap:ProductMember 2024-01-01 2024-03-31 0000914475 nbix:CollaborationRevenueMember 2025-01-01 2025-03-31 0000914475 nbix:CollaborationRevenueMember 2024-01-01 2024-03-31 0000914475 2024-01-01 2024-03-31 0000914475 us-gaap:CommonStockMember 2024-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000914475 us-gaap:RetainedEarningsMember 2024-12-31 0000914475 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000914475 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000914475 us-gaap:CommonStockMember 2025-03-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000914475 us-gaap:RetainedEarningsMember 2025-03-31 0000914475 us-gaap:CommonStockMember 2023-12-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000914475 us-gaap:RetainedEarningsMember 2023-12-31 0000914475 2023-12-31 0000914475 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000914475 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000914475 us-gaap:CommonStockMember 2024-03-31 0000914475 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000914475 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000914475 us-gaap:RetainedEarningsMember 2024-03-31 0000914475 2024-03-31 0000914475 nbix:NxeraPharmaUKLimitedMember us-gaap:CollaborativeArrangementMember 2025-03-31 0000914475 nbix:NxeraPharmaUKLimitedMember us-gaap:CollaborativeArrangementMember 2025-01-01 2025-03-31 0000914475 nbix:TakedaPharmaceuticalCompanyLimitedMember us-gaap:CollaborativeArrangementMember 2025-01-01 2025-03-31 0000914475 nbix:TakedaPharmaceuticalCompanyLimitedMember us-gaap:CollaborativeArrangementMember 2025-03-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2025-01-01 2025-03-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-12-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000914475 nbix:XenonPharmaceuticalsIncMember us-gaap